Sign In
Buy SAN
$12.47
+0.310 (+2.55%)
At Close: Jun 04, 2026
4 Graham-Style Stocks to Consider
12:50pm, Monday, 20'th Jun 2022
To increase your chances of discovering value opportunities, you may want to look for stocks whose Graham blended multipliers are below 22.5. Created by Benjamin Graham, the father of value investing,
Santander Bank Taps Héctor Grisi for Group CEO
06:05pm, Friday, 17'th Jun 2022
Santander Bank named Héctor Grisi as its latest group CEO, effective Jan. 1, as the bank continues to advance its digital transformation plans, according to a press release on Friday (June 17).
Santander picks calm insider as CEO to help build bridges
11:34am, Friday, 17'th Jun 2022
A former investment banker and passionate jogger, Santander's newly-appointed CEO Hector Grisi knows how to bring teams together and motivate staff even as he stands up for his views, executives who h
Banco Santander: Hector Grisi to succeed Jose Antonio Alvarez as CEO
06:15am, Friday, 17'th Jun 2022 MarketWatch
Mr. Alvarez will continue on the board of directors as a nonexecutive vice chair, Santander said.
Banco Santander: Hector Grisi to succeed Jose Antonio Alvarez as CEO
02:15am, Friday, 17'th Jun 2022
By Maitane Sardon
Santander set to appoint Hector Grisi as new CEO - Bloomberg News
01:03am, Friday, 17'th Jun 2022
Spain's Santander is set to appoint insider Hector Grisi as its chief executive officer, replacing long-time executive Jose Antonio Alvarez, Bloomberg News reported on Friday.
FDA says Pfizer three-shot vaccine is safe for children under 5, ahead of panel meeting that will also review Moderna's two-shot regimen
12:13pm, Tuesday, 14'th Jun 2022 MarketWatch
Federal health officials said Sunday that Pfizer's COVID-19 vaccine appears safe and effective for children below the age of five, clearing another hurdle on the path toward adding that group to the n
COVID-variant booster from Sanofi, GSK shows promising results
09:13pm, Monday, 13'th Jun 2022 MarketWatch
A COVID-19 vaccine developed by Sanofi SA and GSK PLC to target the Beta strain of the virus produced a stronger antibody response against variants of omicron when given as a booster compared with
Communiqué de presse: Le vaccin de rappel COVID-19 de Sanofi-GSK induit une forte réponse immunitaire contre les variants préoccupants, dont Omicron
05:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
Le vaccin de rappel COVID-19 de Sanofi-GSK induit une forte réponse immunitaire contre les variants préoccupants, dont Omicron
Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
05:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
Sanofi lance son premier Accélérateur digital porté par de nouveaux talents et centré sur la croissance
09:21am, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
Sanofi lance son premier Accélérateur digital porté par de nouveaux talents et centré sur la croissance
Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth
09:21am, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth
Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
08:45pm, Tuesday, 07'th Jun 2022 GlobeNewswire Inc.
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
Communiqué de presse: La FDA approuve Dupixent® (dupilumab) – premier médicament biologique pour le traitement de la dermatite atopique modérée à sévère de l’enfant âgé de 6 mois à 5 ans
08:45pm, Tuesday, 07'th Jun 2022 GlobeNewswire Inc.
La FDA approuve Dupixent® (dupilumab) – premier médicament biologique pour le traitement de la dermatite atopique modérée à sévère de l’enfant âgé de 6 mois à 5 ans
Sanofi lance son plan mondial 2022 d’actionnariat salarié ouvert à 86 000 salariés
05:30am, Tuesday, 07'th Jun 2022 GlobeNewswire Inc.
Sanofi lance son plan mondial 2022 d’actionnariat salarié ouvert à 86 000 salariés
